The First RAS Inhibitor to Beat Pancreatic Cancer: What Daraxonrasib’s Phase 3 Survival Data Means for Oncology
Revolution Medicines’ daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months for chemotherapy in previously treated metastatic pancreatic cancer, a 60 percent reduction in the risk of…
